Virginia Ronco

Virginia Ronco

Auto-generated profile, based on publicly available information

Virginia Ronco

Pricing Manager MA Provider, Milan, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2013 in Glia
Verified
Journal Article
Closed access
PDF file
DLDmitry Lim
Dmitry Lim
AIAnand M Iyer
Anand M Iyer
VRVirginia Ronco
Virginia Ronco
AGAmbra Grolla
Ambra Grolla
PCPier Luigi Canonico
Pier Luigi Canonico
AGArmando A. Genazzani
Armando A. Genazzani

1 February 2015 in Cell Calcium
Verified
Journal Article
Closed access
VRVirginia Ronco
Virginia Ronco
DPDuilio Michele Potenza
Duilio Michele Potenza
FDFederico Denti
Federico Denti
SVSabrina Vullo
Sabrina Vullo
GGGiuseppe Gagliano
Giuseppe Gagliano
Francesco MocciaFrancesco Moccia
Francesco Moccia

1 April 2014 in Cell Calcium
Verified
Journal Article
Closed access
VRVirginia Ronco
Virginia Ronco
AGAmbra Grolla
Ambra Grolla
TGToma N. Glasnov
Toma N. Glasnov
PCPier Luigi Canonico
Pier Luigi Canonico
Alexei VerkhratskyAlexei Verkhratsky
Alexei Verkhratsky
DLDmitry Lim
Dmitry Lim

17 June 2014
Verified
Book Chapter
Closed access
PDF file
DLDmitry Lim
Dmitry Lim
VRVirginia Ronco
Virginia Ronco
AGAmbra Grolla
Ambra Grolla
Alexei VerkhratskyAlexei Verkhratsky
Alexei Verkhratsky
AGArmando A. Genazzani
Armando A. Genazzani

1 August 2017 in Digestive and Liver Disease
Verified
Journal Article
Open access
PIPietro Invernizzi
Pietro Invernizzi
AFAnnarosa Floreani
Annarosa Floreani
Marco CarboneMarco Carbone
Marco Carbone
MMMarco Marzioni
Marco Marzioni
ACAntonio Craxi
Antonio Craxi
DADomenico Alvaro
Domenico Alvaro
Primary Biliary Cholangitis, previously known as Primary Biliary Cirrhosis, is a rare disease, which mainly affects women in their fifth to seventh decades of life. It is a chronic autoimmune disease characterized by a progressive damage of interlobular bile ducts leading to ductopenia, chronic cholestasis and bile acids retention. Even if the disease usually presents a long asymptomatic phase and a slow progression, in many patients it may progress faster toward cirrhosis and its complications. The 10year mortality is greater than in diseases such as human immunodeficiency virus/Hepatitis C Virus coinfection and breast cancer. Ursodeoxycholic acid is the only treatment available today, but even if effective in counteracting the disease progression for the majority of patients, in approximately 40% is not able to decrease effectively the alkaline phosphatase, a surrogate marker of disease activity. Recently, obeticholic acid received the European Medicines Agency conditional approval, as add on treatment in patients non responders or intolerant to ursodeoxycholic acid. The present paper illustrates the opinion of a working group, composed by clinical pharmacologists, gastroenterologists/hepatologists with specific expertise on Primary Biliary Cholangitis and patient associations, on the state of the art and future perspectives of the disease management. The agreement on the document was reached through an Expert Meeting.